ClinicalTrials.gg
CompletedNCT04718896BE CONNECTEDUpdated Aug 3, 2026Results posted

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of bimekizumab in Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 11 sites in 4 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.

Enrollment
17th of 20
41 · median 161
Started
2021
with 1 other
Phase 2
6 of 20
1 open now
Registered
12th of 20
by date
Lead sponsor
13 of 20
UCB Biopharma SRL

Among the 20 studies testing bimekizumab in Psoriasis, this one is the 17th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 2, and was the 12th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing bimekizumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

Keywords

  • bimekizumab
  • BKZ
  • adolescent study participants
  • psoriasis
  • PSO
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥12 to less than 18 years of age at the time of signing the /assent according to local regulation
  • Participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit and:

    1. Body surface area (BSA) affected by PSO ≥10%
    2. Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)
    3. Psoriasis Area and Severity Index (PASI) score ≥12 OR
    4. PASI score ≥10 plus at least 1 of the following:

    i. facial involvement ii. Clinically relevant genital involvement iii. Clinically relevant hand and foot involvement

  • Participant must be candidate for systemic PSO therapy and/or photo/chemotherapy
  • Body weight ≥30 kg and for age percentile of ≥5 at Baseline
  • Male or female A female participant will be eligible to participate if she is not pregnant, not breastfeeding, and a woman of (WOCBP) agrees to follow the guidance
  • Capable of giving/having parent(s) or legal representative provide signed informed consent/assent (where appropriate)

Exclusion criteria

Exclusion Criteria:

  • Participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO
  • Participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD
  • History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
  • Participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
  • Participant has laboratory abnormalities at Screening
  • Participant has experienced primary failure to one or more interleukin-17 (IL-17) biologic response modifier OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier
  • Presence of active suicidal ideation, or positive suicide behavior
  • Participant has been diagnosed with severe depression in the past 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Bimekizumab Dose A

    Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.

    Drug: bimekizumab

  • Experimental
    Bimekizumab Dose B

    Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.

    Drug: bimekizumab

Interventions

  • Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.

    Also known as: BKZ, UCB4940

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Bimekizumab at Week 0

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 0. PK-PPS = Pharmacokinetic per-protocol set, IMP = investigational medicinal product.

    Time frame: Baseline (Week 0)

  2. Plasma Concentration of Bimekizumab at Week 1

    Blood samples were collected to determine the bimekizumab plasma concentration at Week 1.

    Time frame: Week 1

  3. Plasma Concentration of Bimekizumab at Week 4

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 4.

    Time frame: Week 4

  4. Plasma Concentration of Bimekizumab at Week 8

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 8.

    Time frame: Week 8

  5. Plasma Concentration of Bimekizumab at Week 12

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 12.

    Time frame: Week 12

  6. Plasma Concentration of Bimekizumab at Week 16

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 16.

    Time frame: Week 16

  7. Plasma Concentration of Bimekizumab at Week 20

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 20.

    Time frame: Week 20

  8. Plasma Concentration of Bimekizumab at Week 40

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 40.

    Time frame: Week 40

  9. Plasma Concentration of Bimekizumab at Week 64

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 64.

    Time frame: Week 64

  10. Plasma Concentration of Bimekizumab at Week 88

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 88.

    Time frame: Week 88

  11. Plasma Concentration of Bimekizumab at Week 112

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 112.

    Time frame: Week 112

  12. Plasma Concentration of Bimekizumab at Week 124

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 124.

    Time frame: Week 124

  13. Plasma Concentration of Bimekizumab at Safety Follow up (SFU)

    Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 140 (SFU).

    Time frame: Week 140 (SFU)

Secondary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The last dose was given 4 weeks prior end of extension period.

    Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)]

  2. Percentage of Participants With Serious Treatment-emergent Adverse Events

    An serious adverse event (SAE) must meet 1 or more of the following criteria: Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The data was rounded to one decimal place. The last dose was given 4 weeks prior end of extension period.

    Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)

  3. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Discontinuation of Investigational Medicinal Product (IMP)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason. The last dose was given 4 weeks prior end of extension period.

    Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)

  4. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAEs leading to withdrawal from the study. The last dose was given 4 weeks prior end of extension period.

    Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)

  5. Exposure-adjusted Incidence Rates (EAIR) of Selected Safety Topics of Interest

    Selected safety topics of interest (including infection \[serious, opportunistic, fungal, and tuberculosis (TB)\], inflammatory bowel disease \[IBD\], and injection site reactions) with onset occurring from day of first dose through 20 weeks after final dose of IMP adjusted by duration of participant exposure to IMP. The exposure-adjusted incidence rate (EAIR) is defined as the number of participants (n) with a specific AE adjusted for the exposure and was scaled to 100 participant-years. The last dose was given 4 weeks prior end of extension period.

    Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)

  6. Change From Baseline in Vital Signs (Systolic and Diastolic Blood Pressure)

    Blood pressure was measured in millimeters of mercury (mmHg).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  7. Change From Baseline in Vital Signs (Pulse Rate)

    Pulse rate was measured in beats per minute (beats/min).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  8. Change From Baseline in Vital Signs (Temperature)

    Temperature (oral, axillary, otic or non-contact forehead) was measured in degrees Celsius (°C).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  9. Change From Baseline in Hematology Parameters (Platelet Count)

    Platelets was measured in number of platelets per liter (10\^9/L).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  10. Change From Baseline in Hematology Parameters (Mean Corpuscular Hemoglobin)

    Mean corpuscular hemoglobin (HGB) was measured in picograms (pg).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  11. Change From Baseline in Hematology Parameters (Mean Corpuscular Volume)

    Mean corpuscular volume was measured in femtolitres.

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  12. Change From Baseline in Hematology Parameters (Erythrocytes)

    Erythrocytes was measured in number of red blood cells per liter (10\^12/L).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  13. Change From Baseline in Hematology Parameters (Hemoglobin)

    Hemoglobin was measured in grams per liter.

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  14. Change From Baseline in Hematology Parameters (Hematocrit)

    Hematocrit was measured in volume percentage (%) of red blood cells in the blood.

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  15. Change From Baseline in Clinical Chemistry Parameters (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase)

    Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase was measured in units per liter.

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  16. Change From Baseline in Hematology Parameters (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes)

    Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes was measured in number of white blood cells per liter (10\^9/L).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  17. Change From Baseline in Clinical Chemistry Parameters (Calcium, Potassium, Sodium, Blood Urea Nitrogen, Glucose (Nonfasting)

    Calcium, potassium, sodium, blood urea nitrogen, and glucose (non fasting) was measured in millimoles per liter (mmol/L).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  18. Change From Baseline in Clinical Chemistry Parameters (Creatinine, Total and Direct Bilirubin)

    Creatinine and bilirubin was measured in micromols per liter (μmol/L).

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  19. Change From Baseline in Clinical Chemistry Parameters (Total Protein)

    Total protein was measured in gram per liter (g/L)

    Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)

  20. Change From Baseline in Height

    Growth assessment, as assessed by the change from Baseline in height.

    Time frame: Baseline (Week 0), Weeks 16, 124

  21. Change From Baseline in Weight

    Growth assessment, as assessed by the change from Baseline in weight.

    Time frame: Baseline (Week 0), Weeks 16, 124

  22. Percentage of Participants With Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

    Percentage of participants with PASI 90 response at Week 16 is reported. PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions(on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of average score for redness, thickness, and scaling for each of 4 body areas with score of 0(none) to 4(very marked). Determining percentage of skin covered with psoriasis(PSO) for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved PSO area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.

    Time frame: Week 16

  23. Percentage of Participants With Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] With at Least 2-category Improvement From Baseline) Response at Week 16

    The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline. The data was rounded to one decimal place.

    Time frame: Week 16

  24. Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 Response at Week 4

    Percentage of participants with PASI75 response at Week 4 is reported. PASI75 response assessments are based on at least 75% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions (on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with PSO for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.

    Time frame: Week 4

  25. Percentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Prior to Investigational Medicinal Product (IMP) Administration

    Anti-bimekizumab antibody (AbAb) detection prior to IMP administration. Anti-bimekizumab antibodies was measured using 3-tiered assay approach: screening assay, confirmatory assay, and titration assay. Antidrug antibody (ADAb) positive status: any sample that is positive screen and positive immunodepletion (regardless of availability of a titer value). ADAb negative status: any sample that is either negative screen, or positive screen and negative immunodepletion, and where the bimekizumab concentration is less than or equal to the drug tolerance limit of the validated ADAb assay. ADAb missing status: any sample that is either negative screen or positive screen and negative immunodepletion and where the bimekizumab concentration exceeds the validated ADAb assay drug tolerance limit.

    Time frame: Baseline (Week 0)

  26. Percentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Following Investigational Medicinal Product (IMP) Administration

    Anti-bimekizumab antibody (AbAb) detection following IMP administration. Overall ADAb positive is defined as having at least one sample that is confirmed positive following the 1st dose of IMP to SFU (regardless of missing data). Overall ADAb negative is defined as having all samples reported as negative, or has only one missing/inconclusive sample, following the 1st dose of IMP to SFU. Overall ADAb missing if the study participant has more than one missing ADAb sample for any reason and all other available ADAb samples are negative. The data was rounded to one decimal place.

    Time frame: From Baseline (Week 0, post-first dose) to Safety Follow-Up (Week 140)

  27. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Response at Week 16

    The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week, (ie, over the last 7 days). The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).

    Time frame: Baseline, Week 16

07

Results

Posted May 18, 2026

Participant flow

The study started to enroll participants in April 2021 and concluded in March 2025.

Initial Treatment Period: Weeks 0-20
Participant flow — Initial Treatment Period: Weeks 0-20
MilestoneBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Started2021
Completed1921
Not completed10
Withdrew: Lack of efficacy10
Open-Label Extension: Weeks 20-104
Participant flow — Open-Label Extension: Weeks 20-104
MilestoneBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Started1920
Completed1719
Not completed21
Withdrew: Lack of efficacy01
Withdrew: Consent withdrawn by participant (not due to ae)10
Withdrew: The patient left to study in the usa10

Outcome measures

PrimaryPlasma Concentration of Bimekizumab at Week 0

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 0. PK-PPS = Pharmacokinetic per-protocol set, IMP = investigational medicinal product.

Time frame:
Baseline (Week 0)
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Plasma Concentration of Bimekizumab at Week 0
microgram per milliliter (µg/mL)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 0NA ± NANA ± NA
PrimaryPlasma Concentration of Bimekizumab at Week 1

Blood samples were collected to determine the bimekizumab plasma concentration at Week 1.

Time frame:
Week 1
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 1
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 121.145 ± 33.5103.811 ± 30.424
PrimaryPlasma Concentration of Bimekizumab at Week 4

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 4.

Time frame:
Week 4
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 4
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 411.718 ± 35.2591.986 ± 22.888
PrimaryPlasma Concentration of Bimekizumab at Week 8

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 8.

Time frame:
Week 8
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 8
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 816.344 ± 39.3862.562 ± 91.934
PrimaryPlasma Concentration of Bimekizumab at Week 12

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 12.

Time frame:
Week 12
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 12
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 1219.312 ± 38.2352.600 ± 89.916
PrimaryPlasma Concentration of Bimekizumab at Week 16

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 16.

Time frame:
Week 16
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 16
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 1620.163 ± 41.3232.560 ± 99.017
PrimaryPlasma Concentration of Bimekizumab at Week 20

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 20.

Time frame:
Week 20
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 20
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 2021.579 ± 38.8062.689 ± 99.146
PrimaryPlasma Concentration of Bimekizumab at Week 40

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 40.

Time frame:
Week 40
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 40
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 4020.404 ± 48.7003.354 ± 115.576
PrimaryPlasma Concentration of Bimekizumab at Week 64

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 64.

Time frame:
Week 64
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 64
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 6423.177 ± 42.5053.339 ± 106.934
PrimaryPlasma Concentration of Bimekizumab at Week 88

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 88.

Time frame:
Week 88
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 88
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 8820.342 ± 42.5842.928 ± 107.926
PrimaryPlasma Concentration of Bimekizumab at Week 112

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 112.

Time frame:
Week 112
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 112
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 11218.770 ± 50.4223.017 ± 109.444
PrimaryPlasma Concentration of Bimekizumab at Week 124

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 124.

Time frame:
Week 124
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Week 124
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Week 12417.495 ± 40.7143.104 ± 107.492
PrimaryPlasma Concentration of Bimekizumab at Safety Follow up (SFU)

Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 140 (SFU).

Time frame:
Week 140 (SFU)
Reported as:
Geometric mean · µg/mL
Plasma Concentration of Bimekizumab at Safety Follow up (SFU)
µg/mLBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Plasma Concentration of Bimekizumab at Safety Follow up (SFU)0.762 ± 166.309NA ± NA
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The last dose was given 4 weeks prior end of extension period.

Time frame:
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)]
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)85.081.0
SecondaryPercentage of Participants With Serious Treatment-emergent Adverse Events

An serious adverse event (SAE) must meet 1 or more of the following criteria: Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The data was rounded to one decimal place. The last dose was given 4 weeks prior end of extension period.

Time frame:
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Treatment-emergent Adverse Events
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Percentage of Participants With Serious Treatment-emergent Adverse Events10.014.3
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Discontinuation of Investigational Medicinal Product (IMP)

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason. The last dose was given 4 weeks prior end of extension period.

Time frame:
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Discontinuation of Investigational Medicinal Product (IMP)
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Discontinuation of Investigational Medicinal Product (IMP)5.00
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAEs leading to withdrawal from the study. The last dose was given 4 weeks prior end of extension period.

Time frame:
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study00
SecondaryExposure-adjusted Incidence Rates (EAIR) of Selected Safety Topics of Interest

Selected safety topics of interest (including infection \[serious, opportunistic, fungal, and tuberculosis (TB)\], inflammatory bowel disease \[IBD\], and injection site reactions) with onset occurring from day of first dose through 20 weeks after final dose of IMP adjusted by duration of participant exposure to IMP. The exposure-adjusted incidence rate (EAIR) is defined as the number of participants (n) with a specific AE adjusted for the exposure and was scaled to 100 participant-years. The last dose was given 4 weeks prior end of extension period.

Time frame:
From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Reported as:
Number · events per 100 participants-years
Exposure-adjusted Incidence Rates (EAIR) of Selected Safety Topics of Interest
events per 100 participants-yearsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Serious infection00
Fungal infection4.060
Opportunistic infection (including TB)00
IBD00
Injection site reactions4.350
SecondaryChange From Baseline in Vital Signs (Systolic and Diastolic Blood Pressure)

Blood pressure was measured in millimeters of mercury (mmHg).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · millimetre of mercury (mmHg)
Change From Baseline in Vital Signs (Systolic and Diastolic Blood Pressure)
millimetre of mercury (mmHg)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Systolic Blood Pressure-Week 161.9 ± 8.7-2.1 ± 10.1
Systolic Blood Pressure-Week 124-0.2 ± 13.4-2.1 ± 9.5
Systolic Blood Pressure-SFU2.7 ± 17.50.8 ± 11.3
Diastolic Blood Pressure-Week 16-0.1 ± 9.2-1.7 ± 7.8
Diastolic Blood Pressure-Week 124-0.9 ± 9.9-1.2 ± 6.9
Diastolic Blood Pressure-SFU0.5 ± 5.8-4.0 ± 5.5
SecondaryChange From Baseline in Vital Signs (Pulse Rate)

Pulse rate was measured in beats per minute (beats/min).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · beats/min
Change From Baseline in Vital Signs (Pulse Rate)
beats/minBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-1.1 ± 11.7-3.2 ± 9.5
Week 124-3.0 ± 16.9-1.4 ± 13.7
SFU-5.2 ± 16.2-10.3 ± 15.5
SecondaryChange From Baseline in Vital Signs (Temperature)

Temperature (oral, axillary, otic or non-contact forehead) was measured in degrees Celsius (°C).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · celsius (°C)
Change From Baseline in Vital Signs (Temperature)
celsius (°C)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-0.06 ± 0.330.10 ± 0.25
Week 124-0.19 ± 0.32-0.09 ± 0.19
SFU-0.13 ± 0.310.00 ± 0.18
SecondaryChange From Baseline in Hematology Parameters (Platelet Count)

Platelets was measured in number of platelets per liter (10\^9/L).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · cells*10^9/L
Change From Baseline in Hematology Parameters (Platelet Count)
cells*10^9/LBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-3.1 ± 29.33.6 ± 37.3
Week 124-12.1 ± 58.9-8.1 ± 32.4
SFU-34.1 ± 54.8-29.5 ± 22.4
SecondaryChange From Baseline in Hematology Parameters (Mean Corpuscular Hemoglobin)

Mean corpuscular hemoglobin (HGB) was measured in picograms (pg).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · picograms (pg)
Change From Baseline in Hematology Parameters (Mean Corpuscular Hemoglobin)
picograms (pg)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-0.03 ± 0.64-0.14 ± 0.64
Week 1240.54 ± 1.370.02 ± 1.17
SFU1.32 ± 1.41-0.20 ± 0.52
SecondaryChange From Baseline in Hematology Parameters (Mean Corpuscular Volume)

Mean corpuscular volume was measured in femtolitres.

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · femtoliters
Change From Baseline in Hematology Parameters (Mean Corpuscular Volume)
femtolitersBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-1.22 ± 2.41-1.57 ± 2.13
Week 1241.42 ± 4.08-0.23 ± 4.35
SFU3.54 ± 3.951.98 ± 2.66
SecondaryChange From Baseline in Hematology Parameters (Erythrocytes)

Erythrocytes was measured in number of red blood cells per liter (10\^12/L).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · cells*10^12/L
Change From Baseline in Hematology Parameters (Erythrocytes)
cells*10^12/LBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-0.011 ± 0.2880.039 ± 0.193
Week 124-0.013 ± 0.323-0.017 ± 0.211
SFU-0.152 ± 0.364-0.143 ± 0.151
SecondaryChange From Baseline in Hematology Parameters (Hemoglobin)

Hemoglobin was measured in grams per liter.

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · grams per liter
Change From Baseline in Hematology Parameters (Hemoglobin)
grams per literBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-0.5 ± 7.40.4 ± 4.6
Week 1242.2 ± 12.0-0.4 ± 8.6
SFU1.9 ± 15.7-5.0 ± 2.9
SecondaryChange From Baseline in Hematology Parameters (Hematocrit)

Hematocrit was measured in volume percentage (%) of red blood cells in the blood.

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · % of Red Blood Cells in the blood
Change From Baseline in Hematology Parameters (Hematocrit)
% of Red Blood Cells in the bloodBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-0.72 ± 2.43-0.39 ± 1.85
Week 1240.61 ± 3.79-0.20 ± 3.09
SFU0.32 ± 4.64-0.38 ± 1.47
SecondaryChange From Baseline in Clinical Chemistry Parameters (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase)

Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase was measured in units per liter.

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · units per liter
Change From Baseline in Clinical Chemistry Parameters (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase)
units per literBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Alkaline phosphatase-Week 16-2.0 ± 21.8-2.4 ± 23.5
Alkaline phosphatase-Week 124-52.5 ± 86.8-22.3 ± 47.9
Alkaline phosphatase-SFU-80.1 ± 115.5-19.0 ± 70.1
Alanine aminotransferase-Week 162.9 ± 10.7-1.9 ± 4.4
Alanine aminotransferase-Week 1249.1 ± 18.1-0.6 ± 5.8
Alanine aminotransferase-SFU-0.4 ± 9.8-4.0 ± 9.6
Aspartate aminotransferase-Week 161.4 ± 3.6-1.9 ± 4.7
Aspartate aminotransferase-Week 1242.6 ± 8.0-1.7 ± 5.7
Aspartate aminotransferase-SFU-0.7 ± 8.6-1.8 ± 4.9
SecondaryChange From Baseline in Hematology Parameters (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes)

Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes was measured in number of white blood cells per liter (10\^9/L).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · cells*10^9/L
Change From Baseline in Hematology Parameters (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes)
cells*10^9/LBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Basophils-Week 16-0.002 ± 0.032-0.007 ± 0.027
Basophils-Week 1240.001 ± 0.036-0.006 ± 0.029
Basophils-SFU-0.032 ± 0.0490.005 ± 0.013
Eosinophils-Week 16-0.052 ± 0.2670.006 ± 0.067
Eosinophils-Week 1240.001 ± 0.157-0.006 ± 0.124
Eosinophils-SFU-0.083 ± 0.089-0.050 ± 0.054
Lymphocytes-Week 160.025 ± 0.407-0.105 ± 0.537
Lymphocytes-Week 1240.057 ± 0.705-0.222 ± 0.710
Lymphocytes-SFU-0.124 ± 0.573-0.233 ± 0.378
Monocytes-Week 16-0.069 ± 0.195-0.052 ± 0.141
Monocytes-Week 124-0.064 ± 0.256-0.047 ± 0.156
Monocytes-SFU-0.112 ± 0.1420.063 ± 0.167
Neutrophils-Week 16-0.628 ± 1.145-0.610 ± 1.922
Neutrophils-Week 124-0.522 ± 1.457-0.623 ± 2.342
Neutrophils-SFU-0.109 ± 1.520-0.298 ± 0.721
Leukocytes-Week 16-0.726 ± 1.445-0.763 ± 2.247
Leukocytes-Week 124-0.531 ± 2.038-0.904 ± 2.645
Leukocytes-SFU-0.460 ± 1.663-0.505 ± 1.244
SecondaryChange From Baseline in Clinical Chemistry Parameters (Calcium, Potassium, Sodium, Blood Urea Nitrogen, Glucose (Nonfasting)

Calcium, potassium, sodium, blood urea nitrogen, and glucose (non fasting) was measured in millimoles per liter (mmol/L).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Clinical Chemistry Parameters (Calcium, Potassium, Sodium, Blood Urea Nitrogen, Glucose (Nonfasting)
millimoles per liter (mmol/L)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Calcium-Week 160.014 ± 0.0940.009 ± 0.231
Calcium-Week 124-0.044 ± 0.125-0.013 ± 0.106
Calcium-SFU0.003 ± 0.105-0.058 ± 0.066
Potassium-Week 160.08 ± 0.200.20 ± 0.62
Potassium-Week 1240.04 ± 0.39-0.05 ± 0.31
Potassium-SFU0.04 ± 0.32-0.06 ± 0.36
Sodium-Week 16-0.2 ± 2.00.7 ± 1.6
Sodium-Week 1240.1 ± 1.5-0.5 ± 1.6
Sodium-SFU1.1 ± 1.80.2 ± 1.8
Blood urea nitrogen-Week 160.07 ± 1.010.02 ± 1.12
Blood urea nitrogen-Week 1240.44 ± 1.10-0.18 ± 1.20
Blood urea nitrogen-SFU0.61 ± 1.48-0.04 ± 1.35
Glucose: Week 16-0.039 ± 0.6320.115 ± 0.492
Glucose: Week 124-0.291 ± 0.6550.323 ± 0.746
Glucose: SFU-0.138 ± 0.7660.270 ± 0.593
SecondaryChange From Baseline in Clinical Chemistry Parameters (Creatinine, Total and Direct Bilirubin)

Creatinine and bilirubin was measured in micromols per liter (μmol/L).

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · μmol/L
Change From Baseline in Clinical Chemistry Parameters (Creatinine, Total and Direct Bilirubin)
μmol/LBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Creatinine-Week 16-0.82 ± 9.401.85 ± 4.89
Creatinine-Week 1247.31 ± 11.308.23 ± 6.38
Creatinine-SFU9.83 ± 9.517.94 ± 5.26
Direct Bilirubin-Week 16-0.27 ± 1.66-0.02 ± 1.21
Direct Bilirubin-Week 1240.69 ± 1.96-0.12 ± 0.88
Direct Bilirubin-SFU-0.43 ± 1.050.63 ± 0.46
Total bilirubin-Week 16-0.57 ± 4.510.05 ± 2.94
Total bilirubin-Week 1242.36 ± 6.300.27 ± 2.71
Total bilirubin-SFU-0.80 ± 3.612.08 ± 2.32
SecondaryChange From Baseline in Clinical Chemistry Parameters (Total Protein)

Total protein was measured in gram per liter (g/L)

Time frame:
Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Reported as:
Mean · g/L
Change From Baseline in Clinical Chemistry Parameters (Total Protein)
g/LBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 16-0.2 ± 3.40.1 ± 3.9
Week 1241.1 ± 4.60.7 ± 3.8
SFU-0.2 ± 3.4-1.8 ± 4.2
SecondaryChange From Baseline in Height

Growth assessment, as assessed by the change from Baseline in height.

Time frame:
Baseline (Week 0), Weeks 16, 124
Reported as:
Mean · centimeter (cm)
Change From Baseline in Height
centimeter (cm)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 160.61 ± 1.590.56 ± 1.67
Week 1244.01 ± 6.533.04 ± 5.34
SecondaryChange From Baseline in Weight

Growth assessment, as assessed by the change from Baseline in weight.

Time frame:
Baseline (Week 0), Weeks 16, 124
Reported as:
Mean · kilogram (kg)
Change From Baseline in Weight
kilogram (kg)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Week 162.62 ± 3.200.71 ± 4.11
Week 1244.01 ± 5.995.88 ± 9.64
SecondaryPercentage of Participants With Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

Percentage of participants with PASI 90 response at Week 16 is reported. PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions(on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of average score for redness, thickness, and scaling for each of 4 body areas with score of 0(none) to 4(very marked). Determining percentage of skin covered with psoriasis(PSO) for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved PSO area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 90 Response at Week 1695.090.5
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] With at Least 2-category Improvement From Baseline) Response at Week 16

The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline. The data was rounded to one decimal place.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] With at Least 2-category Improvement From Baseline) Response at Week 16
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Percentage of Participants With Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] With at Least 2-category Improvement From Baseline) Response at Week 1695.090.5
SecondaryPercentage of Participants With Psoriasis Area and Severity Index (PASI) 75 Response at Week 4

Percentage of participants with PASI75 response at Week 4 is reported. PASI75 response assessments are based on at least 75% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions (on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with PSO for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 Response at Week 4
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 Response at Week 480.052.4
SecondaryPercentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Prior to Investigational Medicinal Product (IMP) Administration

Anti-bimekizumab antibody (AbAb) detection prior to IMP administration. Anti-bimekizumab antibodies was measured using 3-tiered assay approach: screening assay, confirmatory assay, and titration assay. Antidrug antibody (ADAb) positive status: any sample that is positive screen and positive immunodepletion (regardless of availability of a titer value). ADAb negative status: any sample that is either negative screen, or positive screen and negative immunodepletion, and where the bimekizumab concentration is less than or equal to the drug tolerance limit of the validated ADAb assay. ADAb missing status: any sample that is either negative screen or positive screen and negative immunodepletion and where the bimekizumab concentration exceeds the validated ADAb assay drug tolerance limit.

Time frame:
Baseline (Week 0)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Prior to Investigational Medicinal Product (IMP) Administration
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Positive00
Negative95.0100
Missing5.00
SecondaryPercentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Following Investigational Medicinal Product (IMP) Administration

Anti-bimekizumab antibody (AbAb) detection following IMP administration. Overall ADAb positive is defined as having at least one sample that is confirmed positive following the 1st dose of IMP to SFU (regardless of missing data). Overall ADAb negative is defined as having all samples reported as negative, or has only one missing/inconclusive sample, following the 1st dose of IMP to SFU. Overall ADAb missing if the study participant has more than one missing ADAb sample for any reason and all other available ADAb samples are negative. The data was rounded to one decimal place.

Time frame:
From Baseline (Week 0, post-first dose) to Safety Follow-Up (Week 140)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Following Investigational Medicinal Product (IMP) Administration
percentage of participantsBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Overall ADAb positive status up to SFU68.445.0
Overall ADAb negative status up to SFU26.355.0
Overall ADAb Missing status up to SFU5.30
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) Response at Week 16

The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week, (ie, over the last 7 days). The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).

Time frame:
Baseline, Week 16
Reported as:
Mean · Scores on a scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Response at Week 16
Scores on a scaleBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Response at Week 16-3.9 ± 5.8-5.5 ± 6.4

Adverse events

Collected over From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BKZ Dose A (320/160 mg)0/20 (0%)2/20 (10%)17/20 (85%)
BKZ Dose B (64/32 mg)0/21 (0%)3/21 (14.3%)17/21 (81%)
Most frequent serious events
Most frequent serious events
EventBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
False positive tuberculosis testInvestigations1/200/21
SyncopeNervous system disorders1/200/21
Intentional product misuseInjury, poisoning and procedural complications0/201/21
Generalised tonic-clonic seizureNervous system disorders0/201/21
EpilepsyNervous system disorders0/201/21
Suicidal ideationPsychiatric disorders0/201/21
Most frequent other events
Showing 10 of 70
Most frequent other events
EventBKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)
NasopharyngitisInfections and infestations9/207/21
Urinary tract infectionInfections and infestations5/203/21
Upper respiratory tract infectionInfections and infestations2/205/21
PharyngitisInfections and infestations2/203/21
Injection site erythemaGeneral disorders2/200/21
RhinitisInfections and infestations2/200/21
ConjunctivitisInfections and infestations2/201/21
Tinea pedisInfections and infestations2/200/21
Limb injuryInjury, poisoning and procedural complications2/200/21
Alanine aminotransferase increasedInvestigations2/200/21

Baseline characteristics

Baseline Characteristics refer to the RS which consisted of all randomized participants.

Age, Continuous
Age, Continuous(years)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)Total
Mean15.1 ± 1.914.6 ± 2.014.8 ± 1.9
Age, Customized
Age, Customized(Participants)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)Total
12 - <18 years202141
Sex: Female, Male
Sex: Female, Male(Participants)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)Total
Female111324
Male9817
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)Total
Black101
White192140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BKZ Dose A (320/160 mg)BKZ Dose B (64/32 mg)Total
Hispanic or Latino011
Not Hispanic or Latino202040
08

Study locations

11 sites
  • Ps0020 50344
    Indianapolis, Indiana 46250, United States
  • Ps0020 50359
    Cypress, Texas 77433, United States
  • Ps0020 50354
    Calgary, Canada
  • Ps0020 50357
    St. John's, Canada
  • Ps0020 40645
    Frankfurt, Germany
  • Ps0020 40626
    Bialystok, Poland
  • Ps0020 40625
    Lodz, Poland
  • Ps0020 40396
    Rzeszów, Poland
  • Ps0020 40335
    Warsaw, Poland
  • Ps0020 40333
    Wroclaw, Poland
  • Ps0020 40334
    Wroclaw, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Mar 2025, 47 months.

Results were first posted in May 2026, 1 year 2 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 47 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 22, 2021
StartActual
Apr 6, 2021
Primary completionActual
Mar 12, 2025
CompletionActual
Mar 12, 2025
Results first posted
May 18, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04718896
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Apr 6, 2021
Primary completion
Mar 12, 2025
Completion
Mar 12, 2025
Results posted
May 18, 2026
Last update
Aug 3, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion